Botanical Ingredient

Cytisine Safety Tips

Handling of Cytisine should only be performed by personnel trained and familiar with handling potent active pharmaceutical ingredients. Moderate to severe irritant to the skin and eyes.

References

• 1. Study on noncovalent complexes of alkaloids with DNA duplex using electrospray ionization mass spectrometry.
  Ma L, Song F, Liu Z, Liu S.Rapid Commun Mass Spectrom. 2013 Jan 15;27(1):51-8. doi: 10.1002/rcm.6424.
• 2. Molecular Determinants of Subtype-Selective Efficacies of Cytisine and the Novel Compound NS3861 at Heteromeric Nicotinic Acetylcholine Receptors.
  Harpsoe K, Hald H, Timmermann DB, Jensen ML, Dyhring T, Nielsen EO, Peters D, Balle T, Gajhede M, Kastrup JS, Ahring PK.J Biol Chem. 2012 Dec 10. [Epub ahead of print]
• 3. Nicotine receptor partial agonists for smoking cessation.
  Cahill K, Stead LF, Lancaster T, Polonio IB.Sao Paulo Med J. 2012;130(5):346-7.
• 4. Nicotinic α4β2 receptor imaging agents. Part IV. Synthesis and Biological Evaluation of 3-(2-(S)-3,4-dehydropyrrolinyl methoxy)-5-(3′-(18)F-Fluoropropyl)pyridine ((18)F-Nifrolene) using PET.
  Pichika R, Kuruvilla SA, Patel N, Vu K, Sinha S, Easwaramoorthy B, Narayanan TK, Shi B, Christian B, Mukherjee J.Nucl Med Biol. 2013 Jan;40(1):117-25. doi: 10.1016/j.nucmedbio.2012.09.009. Epub 2012 Nov 7.
• 5. Synthesis and evaluation of 3-(123)I-iodo-5-[2-(S)-3-pyrrolinylmethoxy]-pyridine (niodene) as a potential nicotinic α4β2 receptor imaging agent.
  Pandey SK, Pan S, Kant R, Kuruvilla SA, Pan ML, Mukherjee J.Bioorg Med Chem Lett. 2012 Dec 15;22(24):7610-4. doi: 10.1016/j.bmcl.2012.10.012. Epub 2012 Oct 10.
• 6. Modulation of α7 Nicotinic Acetylcholine Receptor and Fibrillar Amyloid-β Interactions in Alzheimer’s Disease Brain.
  Ni R, Marutle A, Nordberg A.J Alzheimers Dis. 2012 Oct 5. [Epub ahead of print]
• 7. Cytisine confers neuronal protection against excitotoxic injury by down-regulating GluN2B-containing NMDA receptors.
  Li YJ, Yang Q, Zhang K, Guo YY, Li XB, Yang L, Zhao MG, Wu YM.Neurotoxicology. 2012 Sep 26. doi:pii: S0161-813X(12)00221-5.  10.1016/j.neuro.2012.09.009. [Epub ahead of print]
• 8. Quantitative changes of nicotinic receptors in the hippocampus of dystrophin-deficient mice.
  Ghedini PC, Avellar MC, De Lima TC, Lima-Landman MT, Lapa AJ, Souccar C.Brain Res. 2012 Nov 5;1483:96-104. doi: 10.1016/j.brainres.2012.09.021. Epub 2012 Sep 17.
• 9. Quinolizidine alkaloids from Sophora velutina subsp. zimbabweensis (Fabaceae: Sophoreae).
  Korir E, Kiplimo JJ, Crouch NR, Moodley N, Koorbanally NA.Nat Prod Commun. 2012 Aug;7(8):999-1003.
• 10. CC4, a dimer of cytisine, is a selective partial agonist at α4β2 / α6β2 nAChR with improved selectivity for tobacco smoking cessation.
  Sala M, Braida D, Pucci L, Manfredi I, Marks MJ, Wageman CR, Grady SR, Loi B, Fucile S, Fasoli F, Zoli M, Tasso B, Sparatore F, Clementi F, Gotti C.Br J Pharmacol. 2012 Sep 7. doi: 10.1111/j.1476-5381.2012.02204.x. [Epub ahead of print]
• 11. Förster Resonance Energy Transfer (FRET) Correlates of Altered Subunit Stoichiometry in Cys-Loop Receptors, Exemplified by Nicotinic α4β2.
  Srinivasan R, Richards CI, Dilworth C, Moss FJ, Dougherty DA, Lester HA.Int J Mol Sci. 2012;13(8):10022-40. doi: 10.3390/ijms130810022. Epub 2012 Aug 10.
• 12. Neuronal nicotinic receptor ligands modulate chronic nicotine-induced ethanol  consumption in C57BL/6J mice.
  Sajja RK, Rahman S.Pharmacol Biochem Behav. 2012 Jul;102(1):36-43. Epub 2012 Mar 27.
• 13. Variations in binding among several agonists at two stoichiometries of the neuronal, α4β2 nicotinic receptor.
  Tavares Xda S, Blum AP, Nakamura DT, Puskar NL, Shanata JA, Lester HA, Dougherty DA.J Am Chem Soc. 2012 Jul 18;134(28):11474-80. doi: 10.1021/ja3011379. Epub 2012 Jul 9.
• 14. Live-cell imaging of single receptor composition using zero-mode waveguide nanostructures.
  Richards CI, Luong K, Srinivasan R, Turner SW, Dougherty DA, Korlach J, Lester HA.Nano Lett. 2012 Jul 11;12(7):3690-4. doi: 10.1021/nl301480h. Epub 2012 Jun 8.
• 15. The nicotinic acetylcholine receptor as a target for antidepressant drug development.
  Philip NS, Carpenter LL, Tyrka AR, Price LH.ScientificWorldJournal. 2012;2012:104105. doi: 10.1100/2012/104105. Epub 2012 Apr 24. Review.
• 16. Comparative analysis of quinolizidine alkaloids from different parts of Sophora alopecuroides seeds by UPLC-MS/MS.
  Wang H, Guo S, Qian D, Qian Y, Duan JA.J Pharm Biomed Anal. 2012 Aug-Sep;67-68:16-21. doi: 10.1016/j.jpba.2012.04.024. Epub 2012 Apr 25.
• 17. Use of an α3β4 nicotinic acetylcholine receptor subunit concatamer to characterize ganglionic receptor subtypes with specific subunit composition reveals species-specific pharmacologic properties.
  Stokes C, Papke RL.Neuropharmacology. 2012 Sep;63(4):538-46. doi: 10.1016/j.neuropharm.2012.04.035. Epub 2012 May 11.
• 18. The nicotinic acetylcholine receptors of zebrafish and an evaluation of pharmacological tools used for their study.
  Papke RL, Ono F, Stokes C, Urban JM, Boyd RT.Biochem Pharmacol. 2012 Aug 1;84(3):352-65. doi: 10.1016/j.bcp.2012.04.022. Epub 2012 May 10.
• 19. Cholinergic receptor system as a target for treating alcohol abuse and dependence.
  Rahman S, Prendergast MA.Recent Pat CNS Drug Discov. 2012 Aug;7(2):145-50. Review.
• 20. Structural characterization of binding mode of smoking cessation drugs to nicotinic acetylcholine receptors through study of ligand complexes with acetylcholine-binding protein.
  Rucktooa P, Haseler CA, van Elk R, Smit AB, Gallagher T, Sixma TK.J Biol Chem. 2012 Jul 6;287(28):23283-93. doi: 10.1074/jbc.M112.360347. Epub 2012 May 2.